Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference46 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin.,2021
2. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial;Paz-Ares;The Lancet Oncology.,2021
3. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors;Wang;A Systematic Review and Meta-analysis. JAMA oncology.,2018
4. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;The Lancet Oncology.,2015
5. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors;Suresh;Journal of Thoracic Oncology.,2018
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献